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Major histocompatibility complex class I (MHCI) and class II (MHCII)
molecules display peptides on antigen-presenting cell surfaces for sub-
sequent T-cell recognition. Within the human population, allelic variation
among the classical MHCI and II gene products is the basis for differential
peptide binding, thymic repertoire bias and allograft rejection. While
available 3D structural analysis suggests that polymorphisms are found
primarily within the peptide-binding site, a broader informatic approach
pinpointing functional polymorphisms relevant for immune recognition
is currently lacking. To this end, we have now analyzed known human
class I (774) and class II (485) alleles at each amino acid position using a
variability metric (V). Polymorphisms (V . 1) have been identified in resi-
dues that contact the peptide and/or T-cell receptor (TCR). Using
sequence logos to investigate TCR contact sites on HLA molecules, we
have identified conserved MHCI residues distinct from those of conserved
MHCII residues. In addition, specific class II (HLA-DP, -DQ, -DR) and
class I (HLA-A, -B, -C) contacts for TCR binding are revealed. We discuss
these findings in the context of TCR restriction and alloreactivity.
q 2003 Elsevier Ltd. All rights reserved
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Introduction
Classical major histocompatibility complex
(MHC) molecules are cell-surface glycoproteins
that are central to the process of adaptive immu-
nity, functioning to capture and display peptides
on the surface of antigen-presenting cells (APCs).1
These plasma membrane-bound peptide–MHC
complexes (pMHC) are scrutinized by T-lympho-
cytes via their T-cell receptors (TCRs) during
immunosurveillance.2 Since T-cells recognizing
self-peptides are eliminated during the process of
thymic selection, those pMHC incorporating
foreign peptides are the primary focus of T-cell-
mediated immune responses.3
There are two major classes of MHC molecules,
termed class I and class II.4 MHC class I (MHCI)
molecules are expressed on most cells, bind
endogenously derived peptides with sizes ranging
from eight to ten amino acid residues and are
recognized by CD8 cytotoxic T-lymphocytes
(CTL). On the other hand, MHC class II (MHCII)
are present only on specialized APCs, bind exogen-
ously derived peptides with sizes varying from 9
to 22 residues, and are recognized by CD4 helper
T-cells. These differences indicate that MHCI and
MHCII molecules engage two distinct arms of the
T-cell-mediated immune response, the former tar-
geting invasive pathogens such as viruses for
destruction by CD8 CTLs, and the latter inducing
cytokine-based inflammatory mediators to stimu-
late CD4 helper T-cell activities including B-cell
activation, maturation and antibody production.5
Sequence identity between classical MHCI and
MHCII is low (,20%), yet their 3D structures are
strikingly similar. MHCI molecules are heterodi-
mers composed of a single-membrane-spanning a
chain, paired with the soluble b2 microglobulin
(b2m) protein. The a chain has been divided into
three distinct segments termed a1, a2 and a3. The
a3 region has an immunoglobulin (Ig)-like fold,
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whereas the membrane distal a1 and a2 segments
form a peptide-binding cleft consisting of two a-
helices overlying a floor comprised of eight anti-
parallel b-stranded sheets (a1a2 domain). MHCII
molecules are heterodimers also but comprised of
two subunits, each with a single membrane-span-
ning anchor. The extracellular segment of the a
chain includes a1 and a2 domains, and likewise,
the b chain is composed of b1 and b2 domains. In
the mature MHCII molecule, the a2 and b2
domains fold as independent Ig-like domains,
whereas a1 and b1 fold together, creating a single
antigen-presenting platform with architecture very
similar to that of the a1a2 domain in MHCI
molecules.6,7
In the human, MHC molecules are referred to as
HLA, an acronym for human leukocyte antigens,
and are encoded by the chromosome 6p21.3-
located HLA region.8,9 The HLA segment is
divided into three regions (from centromere to tel-
omere), class II, class III and class I. Classical class
I and class II HLA genes are contained in the class
I and class II regions, respectively, whereas the
class III locus bears genes encoding proteins
involved in the immune system but not structu-
rally related to MHC molecules. The classical
HLA class I molecules are of three types, HLA-A,
HLA-B and HLA-C. Only the a chains of these
mature HLA class I molecules are encoded within
the class I HLA locus by the respective HLA-A,
HLA-B and HLA-C genes. In contrast, the b2m
chain encoded by the b2m gene is located on
chromosome 15. The classical HLA class II mol-
ecules are also of three types (HLA-DP, HLA-DQ
and HLA-DR), with both the a and b chains of
each encoded by a pair of adjacent loci. In addition
to these classical HLA class I and HLA class II
genes, the human MHC locus includes a long
array of HLA pseudogenes as well as genes encod-
ing non-classical MHCI and MHCII molecules.9
HLA-pseudogenes are an indication that gene
duplication is the main driving force for HLA
evolution,10 whereas non-classical MHCI and
MHCII molecules often subserve a restricted func-
tion within the immune system quite distinct from
that of antigen presentation to ab TCRs.11,12 Fur-
thermore, in contrast to the classical HLA mol-
ecules (with the exception of the somewhat
polymorphic MICA and MICB genes), non-classical
HLA molecules are composed of a very limited
number of allelic variants.
Genes encoding classical HLA molecules are
extremely polymorphic, such that most classical
HLA genes include a large number of allelic var-
iants. Thus, the HLA IMGT/HLA database†13 cur-
rently includes 1524 HLA allelic sequences (904
HLA I alleles and 620 HLA II alleles) (release 1.16,
14/10/2002). The basis for this extreme level of
allelic diversity has been linked to evolving optim-
ization of immune protection against pathogens.
Consistent with this notion, most polymorphisms
are associated with the peptide-binding residues
of the a1a2 and a1b1 domains of HLA class I and
HLA class II molecules, respectively.14 Moreover,
the rate of non-synonymous substitutions (those
that result in amino acid changes) is greater than
the rate of synonymous substitutions (those that
do not change amino acid sequence) in codons spe-
cifying amino acids involved in peptide
binding.15,16 In addition, population studies of
HLA class I genes indicate that codons involved
in peptide binding have greater heterozygosity
than those with other functions.17 Reproductive
selection mechanisms may contribute toward shap-
ing the HLA polymorphisms.18
HLA molecular variability studies at an amino
acid level are limited,19 as most HLA polymorph-
ism analyses have been performed at the nucleo-
tide level. Thus, comprehensive analysis of HLA
amino acid variability in the context of the ever-
increasing number of pMHC structures, some in
complex with cognate TCRs, is missing. In this
regard, we have carried out a detailed analysis of
the amino acid sequence variability in each of the
six distinct classical HLA molecules (HLA-A,
HLA-B, HLA-C, HLA-DP, HLA-DQ, and HLA-
DR) using a variability metric given by the Shan-
non entropy equation.20 We have combined this
variability metric with sequence contact maps of
the MHC binding to peptides, TCRs and CD8 and
CD4 co-receptors obtained from the analysis of the
available X-ray crystallographic structures. Inter-
estingly, the pattern of variability for every MHC
molecule distinguishes MHCI and MHCII and
defines characteristic “fingerprints” for each sub-
class. The relevance of these distinct patterns of
variability in MHC peptide-binding specificity, as
well as TCR restriction and alloreactivity is dis-
cussed. Sequence variability analysis of the peptide
binding region of HLA molecules and their map-
ping onto the relevant 3D structures is available
for visualization at the Molecular Immunology
Foundation web site‡.
Results and Discussion
HLA polymorphisms
HLA genes are extremely polymorphic, with
most genes consisting of a large number of allelic
variants (Table 1) specifying differences at the
amino acid level and fine structural detail as
revealed by X-ray crystallography comparison of
PDBs (Table 2). The number of HLA allelic variants
that diverge in at least one amino acid residue var-
ies for the individual HLA genes, being greatest for
HLA-B and DRB1 genes with 447 and 271 variants,
respectively (Table 1). At the other extreme is the
HLA-DRA gene, with only two allelic variants
† http://www.ebi.ac.uk/imgt/hla/ ‡ http://mif.dfci.harvard.edu/Tools/hla_seqanal.html
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encoding for proteins that differ at the amino acid
level. The number of amino acid differences
between HLA alleles varies among HLA genes.
Thus, the two different HLA-DRA gene products
differ at only one amino acid position. In contrast,
HLA-A and HLA-B gene products differ at ,19
residue positions (i.e. ,5% of the protein
sequence) (Table 3). Moreover, as shown in Table
3, most of the differences localize to the antigen-
presenting a1a2 domain of HLA class I molecules,
and the equivalent a1b1 domain of HLA class II
molecules. For example, among HLA-A alleles,
there are 5.42% overall differences throughout the
entire molecule but 9.05% within the a1a2 domain.
The functional relevance of discrete protein vari-
able segments was first elucidated by E. A. Kabat,
who predicted that the highly variable sites in
immunoglobulin molecules were contacts for
antigen,21 antedating crystallographic resolution of
antibody–antigen complexes. By analogy, the
extreme number of HLA allelic variants would
suggest that HLA polymorphic sites per se are func-
tionally significant, even if structural detail is lack-
ing for all HLA gene products.
Detection of HLA polymorphisms
HLA polymorphisms (variable sites) can be
detected from multiple sequence alignments of
allelic variants using the traditional Wu-Kabat
variability coefficient21 where the variability index
is defined as the number of different symbols
(amino acids) found at a site divided by the rela-
tive frequency of the most common amino acid at
the site. In the current study, we have investigated
HLA sequence variability and polymorphisms
using a second variability metric (V) (equation (1)
in Materials and Methods) that has proven to be a
robust tool for the analysis of sequence variability
in related systems.22 This variability metric is
formally identical with that of the Shannon entropy
equation.20 However, it is important to stress that
we have not performed a bona fide Shannon
entropy analysis of HLA diversity in the human
population, which would require consideration of
HLA sampling issues, taking into consideration
the frequency of all the alleles in the human popu-
lation. Instead, we have adopted this equation as a
variability metric to study sequence variability
Table 1. HLA protein sequences included in this variabil-
ity analysis
HLA Molecule Sequence
Class I
HLA-A 230
HLA-B 447
HLA-C 97
Class II
HLA-DPA1 12
HLA-DPB1 90
HLA-DQA1 17
HLA-DQB1 42
HLA-DRA 2
HLA-DRB1 271
HLA-DRB3 30
HLA-DRB4 7
HLA-DRB5 14
In the case of HLA-DR, the a chains (HLA-DRA) derive from
the HLA-DRA gene loci, whereas the b chain counterpart
(HLA-DRB) derives from four different HLA-DRB genes,
namely HLA-DRB1, HLA-DRB3, HLA-DRB4 and HLA-DRB5.
Sequences included in this analysis differ in at least one amino
acid.
Table 2. PDB files with the 3D structures of MHC molecules from which HLA contacts with peptide, TCR, CD4 and
CD8 were obtained
PDB
Class I Class II
Contact HLA-A HLA-B HLA-C Kb a
HLA-
DP
HLA-
DQ HLA-DR IAk a
Peptide 1HHJ;1AKJ;1HHK;
1AO7;1BD2;1B0G;
1HHG;1HHI;1B0R;
2CLR;1HHH;1I1Y;
1I1F;1DUZ;1DUY;
1IM3;1QSF;1QSE;
1QRN;1JF1;1JHT;
1I7T;1I7R;1I7U;
1I4F;1TMC
1AGB;1AG;C1AGD;
1AGE;1AGF;1HSA;
1A1N;1A9E;1A9B;
1E27;1E28;1A1M;
1A1O
1IM9;1EFX Model 1JK8 1AQD;1DLH;1SEB;
1FYT;1HXY;1KG0;
1BX2;2SEB;1J8H;
1A6A
TCR 1AO7;1QRN;1QSE1QSF;
1BD2
NA NA 1G6R;1JTR
2CKB;
1FO0;1KJ2
NA NA 1FYT;1J8H 1D9K
CD8 1AKJ NA NA 1BQH Do not bind CD8
CD4 Do not bind CD4 NA NA NA 1JL4
NA, not available.
a These are mouse MHC molecules.
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and polymorphisms among the available HLA
sequences.
Given a multiple sequence alignment, V per site
ranges from 0 (totally conserved site) to 4.3 (all 20
amino acids are present, and at the same fre-
quency). In an absolute sense, any site with V . 0
is polymorphic. However, several V ranges can be
designated to categorize polymorphic sites of
HLA molecules based on the frequency of the
different amino acids present at a given site. Con-
sidering only two different amino acids per site, a
value of V ¼ 0.5 will be obtained with a ratio
between the two amino acids of 1.1:8.9 (given 100
sequences with 11 containing one amino acid and
89 containing a second amino acid at the same pos-
ition). Moreover, a value of V ¼ 1 can be reached
only when both amino acids are represented
equally (1:1 ratio). On the other hand, in a site
where there are only three different amino acid
types, a ratio of 1.0:1.1:7.9 (given 100 sequences:
10, 11, and 79 with amino acids of each type),
yields a value of V . 1. From these considerations,
we regard sites with V , 0.5 as low significance
polymorphisms (90% or more of the amino acids
are of the same type), the sites with V between 0.5
and 1 (0.5–1) as dimorphic, and the sites with
V . 1 as polymorphic. Note, that these ranges of
V defined here represent a simplification that will,
however, be useful to study HLA polymorphisms
and their correlation with key structural and func-
tional features. However, these V ranges are mean-
ingful only within the HLA system.
Sequence variability analysis of HLA molecules
In Figure 1, we have analyzed the variability of
HLA class I molecules considering all sequences
together (774 sequences), or separated into the
HLA-A, HLA-B or HLA-C subtypes (230, 447 and
97 sequences, respectively; see also Table 1). Like-
wise, we have analyzed the variability of both of
the a and b chains of HLA class II molecules
(Figure 2), when pooled or as products of separate
genes. Variability plots of the combined HLA class
I molecules (Figure 1(A)) are very similar to those
of the individual HLA-A, HLA-B, and HLA-C
alleles, with the only significant differences show-
ing in the transmembrane and (TM) and cyto-
plasmic (CYT) regions. However, some of this
variability might be a consequence of the CLUS-
TALW analysis, since the CYT region of HLA class
I sequences can vary in length, fostering sequence
misalignment. Variability plots from combined
HLA class II a chain sequences, and combined
HLA class II b chain sequences are quite different
from those obtained when allelic sequences are
separated by genes (Figure 2). This difference
indicates that the three HLA class II genes (HLA-
DP, HLA-DQ, and HLA-DR) are more dissimilar
to each other than HLA class I genes (HLA-A,
HLA-B, and HLA-C). Consistent with this notion,
classical HLA class II genes seem to have diverged
earlier than classical HLA class I.10 Thus, we have
studied the variability of the individual HLA
molecules in a gene-specific manner to elucidate
functional features related to sequence variability,
thereby eliminating variation due to sequence
divergence between the distinct genes. Moreover,
this approach prevents the detection of sequence
variability resulting from CLUSTALW artifacts.
The one exception involves the HLA-DR b chains
(HLA-DRB) encoded by four different genes
(HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5).
We analyzed the products of all these genes
together, since these molecules are highly similar
and form heterodimers with the same HLA-DR a
chains (HLA-DRA).
In this study we have distinguished between the
leader, a1, a2, a3, TM and CYT segments of HLA
class I molecules. Likewise, we have distinguished
the a1, a2, TM, and CYT of the a chains (HLA-
DPA, HLA-DQA and HLA-DRA), and the corre-
sponding segments (b1, b2, TM, and CYT) of the
b chains (HLA-DPB, HLA-DQB and HLA-DRB)
for HLA class II molecules. The number of variable
sites within different V ranges and their segmented
location is summarized in Table 4. The number of
positions with more than one amino acid (V . 0)
is truly remarkable for class I. Thus, for HLA-A,
HLA-B, and HLA-C, 168 of 365, 176 of 363, and
Table 3. Amino acid changes between different HLA alleles: full length and peptide binding region
Full length a1a2 (a1b1) peptide-binding region
MHC Difference % Difference Residues Difference % Difference Residues
HLA-A 19.79 ^ 9.56 5.42 365 16.20 ^ 6.69 9.05 179
HLA-B 18.15 ^ 8.01 5.00 363 15.89 ^ 5.66 8.88 179
HLA-C 13.33 ^ 6.74 3.64 366 10.72 ^ 3.71 5.99 179
HLA-DPA 2.90 ^ 2.33 1.11 260 1.64 ^ 1.01 2.22 74
HLA-DPB 9.01 ^ 5.56 3.4 258 7.63 ^ 3.54 8.7 87
HLA-DQA 16.72 ^ 9.87 6.56 255 12.67 ^ 7.49 16.90 75
HLA-DQB 13.75 ^ 7.53 5.27 261 12.53 ^ 6.04 14.40 87
HLA-DRA 1.0 ^ 0.0 0.4 254 0 0 74
HLA-DRB 11.04 ^ 4.68 4.15 266 10.40 ^ 4.22 11.96 87
Values correspond to mean ^ standard deviation. Amino acid (aa) changes between HLA alleles depends on the individual identity
of alleles considered, and therefore mean differences with standard deviation were calculated from all-against-all pairwise
comparisons.
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103 of 366 positions respectively, are subject to
amino acid change. In contrast, in class II, with
the exception of the HLA-DRB possessing 106
sites with V . 0, the number of variable positions
is much smaller. Also, in HLA class II, aside from
HLA-DQ, the a chains have many fewer variable
positions than the b chains. The extreme case
occurs with HLA-DR. Thus, there are only two
known HLA-DRA variants differing by just one
amino acid within the TM domain (Figure 2(D);
Table 4). Despite the large number of variable pos-
itions in HLA molecules, Table 4 shows that most
have V , 0.5. Many fewer positions qualify as
dimorphic or polymorphic.
Variable sites (V . 0) are distributed throughout
the sequence of HLA class I molecules, although
with some preference for the a1 and a2 regions.
However, dimorphic sites (0.5 # V # 1) and most
notably polymorphic sites (V . 1) are concentrated
in the a1 and a2 regions (Table 4). Moreover, the
density of polymorphic sites (defined as sites with
V . 1 divided by the total domain length) is larger
in the a1 and a2 regions than in the remaining
domains. In HLA class II molecules, the variable,
dimorphic and polymorphic sites are most concen-
trated in the a1 and b1 segments. In summary,
polymorphic residues are preferably localized to
the a1a2 domain of HLA class I and the a1b1
domain of HLA class II molecules where peptide
binding and TCR-based immune recognition
occurs.23,24 The relationship between the poly-
morphic sites and the function of these domains
are discussed below.
There are also some polymorphic sites (V . 1)
that are not restricted to the antigen-presenting
platform of HLA class I and HLA class II (Table 4).
The selective pressure driving these polymorph-
isms is unknown. Polymorphisms in the a3
domain of MHC class I molecules are of
particular interest, since this domain binds the
Figure 1. The Figure shows sequence variability corresponding to all HLA class I molecules (A), and to each of the
HLA-A, HLA-B, and HLA-C types (B, C and D, respectively). Sequence variability was calculated from the relevant
multiple sequence alignments using the variability metric (V), and plotted for each site/position in the alignment. V
can range from 0 (totally conserved site) to 4.3 (most variable, with all 20 amino acids represented equally at the
site), and the value of V ¼ 1 is highlighted. Positions with V . 1 are polymorphic. The signal sequence (SIG), anti-
gen-presenting domain (a1a2 domain), a3 domain, transmembrane (TM) and cytosolic (CYT) region of HLA class I
molecules are shown under the variability plots. The box in the a3 domain indicates loop residues 225–232 interacting
with CD8. The CD8 contacts were obtained from the analysis of the X-ray structure of HLA-Ap0201 in complex with
human CD8 (PDB: 1AKJ). Sequence numbering is from the X-ray structures of pMHC complexes and starts after the
leader sequence.
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CD8 co-receptor and associates with b2m. The CD8
co-receptor is an important component of the
pMHCI recognition complex, binding in a
bidentate manner to the same pMHC molecule
ligated by the TCR, and thus helping to form a
stable interaction.25,26 No polymorphic site was
located in a position contacting CD8. Indeed, the
primary CD8 contact involving a flexible loop
(residues 223–229) of the MHC a3 domain25 is
virtually free of variability in the three distinct
HLA class I molecules (Figure 1). Moreover, the
sequence of this loop is conserved among the
three HLA class I molecules (Figure 1(A)). HLA-A
and HLA-B allotypes (HLA-A68, HLA-B48, and
Figure 2. Sequence variability within all HLA class II a chains (A), and from each of the HLA class II gene HLA-DP,
HLA-DQ, and HLA-DR a chains (B, C and D, respectively) was calculated from the relevant multiple sequence align-
ments using V and plotted for each site/position in the alignment. Likewise, E, F, G and H show variability plots
within the HLA class II b chains. The value of V ¼ 1, above which a site is always polymorphic, is indicated. Signal
sequence (SIG), a1 antigen-presenting region, a2 domain, transmembrane (TM) and cytosolic (CYT) of the HLA class
I a chains are indicated under their variability plots. Also indicated under the variability plots of HLA class II b chains
are the equivalent regions SIG, b1, and b2, TM and CYT. The region in the a domain that appears boxed encompasses
positions 88–92 that contact the CD4 co-receptor. In the b domains, the position 142–148 and 156–158 also interact
with the CD4 co-receptor, and are indicated with boxes. CD4 contacts were extrapolated from those obtained from
the X-ray structure of mouse IAk in complex with human CD4 (PDB: 1JL4). Sequence numbering is that of the X-ray
structure of pMHC complexes and starts after the leader sequence.
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HLA-B81) have been described with impaired CD8
binding due to substitution at position 245 of the
a3 domain, however.27,28 Position 245 is an Ala in
almost all HLA class I alleles. This residue is bur-
ied in the structure of the a3 domain and not
directly accessible for contact by CD8. However,
A245 is adjacent to the flexible a3 loop interacting
with CD8 such that an A245 mutation can result
in a local distortion, thereby disrupting the binding
of CD8.25 Position 245 has a V value of 0.451, 0.145
and 0, for the HLA-A, HLA-B and HLA-C, respect-
ively. Thus, this position will be substituted more
frequently in HLA-A than it is in HLA-B, and is
constant in HLA-C. Not surprisingly, no HLA-C
allotype has been described with impaired CD8
binding due to a change at residue 245. Note that
position 245 has some degree of variability but
this is under the threshold (0.5) that we set to
define dimorphic sites. This finding illustrates that
any allelic polymorphism can have an impact on
the structure and function of a given HLA
molecule.
HLA class II molecules engage CD4 as their co-
receptor.29 CD4 interacts with a hydrophobic
pocket created by residues located in the a2 and
b2 domains of HLA class II molecules. The a2
domain residues contacting CD4 show virtually
no variability (Figure 2). Moreover, this region is
identical between the HLA-DPA, HLA-DQA, and
HLA-DRA chains (Figure 2(A)). CD4 contacts with
individual HLA class II b chains (HLA-DPB,
HLA-DQB, and HLA-DRB) show little variability
(Figure 2(F)–(H)). However, when all HLA class II
b chains were analyzed together (Figure 2(E)),
position 145 had a significant variability (V . 1),
indicating that this residue varies between the
HLA-DPB, HLA-DQB, and HLA-DRB chains. This
difference was somewhat unexpected, given that
CD4 interaction is a feature common to the three
classical HLA class II molecules. Nevertheless,
Table 4. Variable sites in classical HLA molecules and their location for different V ranges
HLA Class I
V Leader a1 a2 a3 TM CYT Total
HLA-A .0 9 (36) 44 (49.4) 51 (57.3) 50 (48.5) 8 (36.4) 6 (16.7) 168
0.5–1 2 (8.0) 8 (9.0) 12 (13.5) 4 (3.9) 4 (18.2) 4 (11.1) 34
.1 0 (0.0) 6 (6.7) 7 (7.9) 3 (2.9) 0 (0.0) 0 (0.0) 16
HLA-B .0 17(70.8) 42 (46.6) 63 (7.0) 45 (44.1) 6 (27.3) 3 (8.6) 176
0.5–1 4 (16.6) 11 (12.2) 8 (8.8) 2 (2.0) 1 (4.6) 2 (5.7) 28
.1 2 (8.3) 8 (8.9) 7 (7.8) 0 (0.0) 0 (0.0) 0 (0.0) 17
HLA-C .0 6 (25.0) 18 (20.0) 22 (24.4) 15 (14.2) 10 (45.4) 32 (91.4) 103
0.5–1 2 (8.3) 8 (8.0) 6 (5.7) 5 (22.7) 2 (5.7) 2 (5.7) 31
.1 1 (4.2) 3 (3.3) 6 (6.6) 2 (1.9) 1 (4.55) 1 (2.9) 14
HLA Class II
V Leader a1 b1 a2(b2) TM CYT Total
HLA-DPA .0 0 (0.0) 10 (11.9) – 5 (4.7) 0 (0.0) 1 (7.1) 16
0.5–1 0 (0.0) 5 (6.0) – 5 (4.7) 0 (0.0) 1 (7.1) 11
.1 0 (0.0) 0 (0.) – 0 (0.0) 0 (0.0) 0 (0.0) 0
HLA-DPB .0 0 (0.0) – 22(25.0) 2 (1.8) 0 (0.0) 0 (0.0) 24
0.5–1 0 (0.0) – 8 (9.1) 1 (0.9) 0 (0.0) 0 (0.0) 9
.1 0 (0.0) – 8 (9.1)) 0 (0.0) 0 (0.0) 0 (0.0) 8
HLA-DQA .0 5 (17.9) 27 (32.9) – 9 (8.3) 2 (9.1) 1 (6.7) 44
0.5–1 3 (10.7) 16 (19.5) – 7 (6.5) 1 (4.5) 1 (6.7) 28
.1 0 (0.0) 6 (7.3) – 1 (0.9) 0 (0.0) 0 (0.0) 7
HLA-DQB .0 6 (18.8) – 32 (35.6) 10 (9.3) 2 (8.7) 1 (12.5) 51
0.5–1 6 (18.8) – 13 (14.4) 8 (7.4) 2 (8.7) 1 (12.5) 30
.1 0 (0.0) – 9 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 9
HLA-DRA .0 0 (0.0) 0 (0.0) – 0 (0.0) 1 (5.2) 0 (0.0) 1
0.5–1 0 (0.0) 0 (0.0) – 0 (0.0) 1 (5.2) 0 (0.0) 1
.1 0 (0.0) 0 (0.0) – 0 (0.0) 0 (0.0) 0 (0.0) 0
HLA-DRB .0 9 (31.0) – 61 (67.8) 29 (26.9) 2 (8.7) 5 (31.2) 106
0.5–1 8 (27.6) – 10 (11.1) 10 (9.3) 0 (0.0) 3 (18.8) 31
.1 0 (0.0) – 14 (15.6) 2 (1.9) 0 (0.0) 0 (0.0) 16
Values indicate the number of sites with the specified variability in the different HLA domains, followed the density (in parenth-
eses) of variable sites defined as the percentage of variable position divided by the domain length. Domain boundaries used to derive
domain sizes needed for these calculations were obtained from the relevant consensus sequences using SMART69 and were the same
as those of reported X-ray structures. Consensus sequences were derived from the relevant amino acid sequence alignments. Boxes
labeled with “–” indicate that the corresponding HLA molecule (leftmost in row) does not contain a particular domain (top in col-
umn).
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examination of the reported X-ray crystal structure
of CD4-MHCII29 indicates that the CD4 domain 1
C00 strand forms an extended b sheet with the
MHCII b2 domain D strand, which encompasses
Ser143-Thr145 and, as such, the side-chain of resi-
due 145 is not constrained by any specific amino
acid side-chain at that position.
Sequence variability and peptide/TCR contacts
in the peptide-recognition domain of
HLA molecules
To investigate the functional significance of HLA
polymorphisms in the antigen-presenting plat-
form, we have combined HLA sequence variability
analysis with HLA sequence contact maps enumer-
ating those interactions with peptide and TCR. The
combination of sequence variability and contact
maps is shown in Figure 3 for HLA class I and in
Figure 4 for HLA class II. Most HLA residues
identified as peptide contacts (see Materials and
Methods) were identical among the specific HLA
molecule subtypes belonging to the same class.
Several contacts are distinct, implying a different
peptide binding mode and/or differences
arising from the limited set of peptide–MHC
structures analyzed. Although HLA TCR contact
residues were obtained from a limited number of
Figure 3. Sequence variability and peptide and/or TCR contacts in the antigen-presenting a1a2 domain of HLA
class I molecules. Sequence variability within the a1 and a2 domain of HLA-A (A1 and A2), HLA-B (B1 and B2), and
HLA-C (C1 and C2), are plotted against their corresponding consensus sequences. Variability was calculated using
equation (1) from the relevant multiple sequence alignment. Consensus sequences were derived from the relevant
alignment as the most abundant amino acid at every position. The polymorphism threshold value of V ¼ 1 is indicated
with a red line. Secondary structure elements are indicated under the consensus sequences (red arrows for b-strands
and blue cylinders for a-helices), and are labeled following the nomenclature given by the PDBsum database.68
Positions that are in contact with the peptide are indicated with an inverted triangle under the consensus sequences.
Black triangles indicate residues that form part of the binding pockets of the relevant HLA molecule contributing to
the binding properties and specificity of the HLA molecule. In contrast, blue triangles point out HLA residues that
are in proximity to the peptide but likely do not contribute to the specificity and binding properties of the molecule.
MHC residues that are potential contacts for the TCR Va chain are shadowed in red, and shadowed in blue are poten-
tial contacts for the TCR Vb chains. Shadowed in green are those residues that can be contacted by both the TCR Va
and TCR Vb chains. TCR and peptide contacts were obtained from the analysis of the structures indicated in Table 2,
and represent a summation of all possible contacts obtained from the analysis of all the structures as indicated in
Materials and Methods. Therefore, due to the flexibility of interaction of both the peptide and TCR with the MHC, a
given peptide and/or TCR will not necessarily engage in all the contacts indicated in the Figure. Moreover, as the
numbers of X-ray structures increase, it is possible that new contacts will be found.
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pMHC–TCR 3D structures (Table 2), these are
considered to be comparable for all the MHC
molecules belonging to the same class (MHCI or
MHCII), given that their 3D structure and
geometry are almost identical. The number of
different peptide and TCR contact residues identi-
fied in HLA class I molecules was 40 and 30,
respectively (Figure 3). Likewise, in HLA class II,
the number of residues identified as making pep-
tide and TCR contacts was 45 and 23, respectively.
Note that only primary HLA peptide residue con-
tacts (those indicated with black triangles in
Figures 3 and 4) have been considered in this
enumeration of peptide contacts. Peptides binding
to MHCII molecules often extend beyond the
boundaries of the binding groove, with only a
core of nine residues fitting into the binding
groove.6,7 Thus, in HLA class II molecules we have
considered as primary peptide contacts those resi-
dues interacting with the peptide core. Neverthe-
less, in Figure 4 we have indicated the HLA class
II residues that interact with flanking regions of
the peptide (shown as inverted white triangles).
There are additional HLA class I and class II resi-
dues in close proximity to the peptide, that have
not been tallied as primary peptide contacts
(shown as inverted blue triangles in Figures 3 and
4) as visual inspection of the 3D structures indi-
Figure 4. Sequence variability and peptide and/or TCR contacts in the antigen-presenting a1b1 domain of HLA
class II molecules. Sequence variability within the a1b1 antigen-presenting domain of HLA-DP (A1 and A2), HLA-
DQ (B1 and B2), and HLA-DR (C1 and C2) was obtained using the V metric from the relevant multiple sequence align-
ments, and plotted against their corresponding consensus sequences. In the case of HLA-DRA, only the consensus
sequence is shown (C1), since the only two known allelic variants (DRAp0101 and DRAp0102) have identical
sequences in the a1 region. Secondary structure elements are indicated under the consensus sequences (using symbols
defined in the legend to Figure 3). Sequence variability and consensus sequences were obtained from the relevant
amino acid sequence alignments as indicated in Figure 3. The polymorphism threshold value of V ¼ 1 is indicated
with a red line on the variability plots. Positions that are in contact with the peptide are indicated by inverted triangles
under the consensus sequences. Black triangles indicate residues that contribute to the binding properties and speci-
ficity of the relevant HLA molecule, whereas blue triangles point out HLA residues that are in proximity to the peptide
but likely do not contribute to the specificity and binding properties of the molecule. White triangles point to HLA
class II residues interacting with flanking regions of the peptide core extending beyond the binding groove. As for
Figure 3, MHC residues that are potential contacts for the TCR Va chain are shadowed in red, shadowed in blue are
potential contacts for the TCR Vb chains, and shadowed in green are the residues that can be contacted by both the
TCR Va and TCR Vb chains. Also as for HLA class I molecules, these represent a summations of all possible contacts
obtained from the analysis of the set of X-ray crystal structures (Table 2; Materials and Methods), and therefore a
given peptide and/or TCR will not necessarily engage in all the contacts indicated in the Figure.
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cated that they are not likely to contribute to pep-
tide binding. Interestingly, for both class I and
class II molecules, many of the residues identified
as TCR contacts are also forming peptide contacts
(Figures 3 and 4). The number of residues ident-
ified as TCR contacts is somewhat greater in HLA
class I than in HLA class II molecules. This differ-
ence is primarily due to the fact that there are
currently more available 3D structures of TCR–
pMHCI complexes than TCR–pMHCII and the
former apparently manifests greater docking
variability.30 Note that the listed HLA-TCR residue
contacts represent a summation of all HLA resi-
dues found to be within 5 A˚ of the TCR in existing
TCR–pMHC crystallographic structure: these are
not tallied as atomic contacts but rather as residue
contacts.
A summary of the V . 0, 0.5 # V # 1 and V . 1
sites contacting peptide or TCR is shown Table 5.
Also listed are the total number of variable sites
within the indicated V ranges present in the HLA
class I and HLA class II (a þ b chains) full-length
molecules as well as the corresponding a1a2 and
a1b1 domains. Analysis of these results indicates
that the HLA peptide contact residues account for
most of the V . 1 sites observed in the antigen-
presentation domains of HLA class I and HLA
class II molecules (nine of 13 in HLA-A, 14 of 15
in HLA-B, nine of nine in HLA-C, eight of eight in
HLA-DP, nine of 15 in HLA-DQ, and ten of 14 in
HLA-DR). Thus, the numbers of HLA TCR contact
residues that are V . 1 (polymorphic) is much
smaller than that of peptide contact residues. Fur-
thermore, virtually all V . 1 residues that are TCR
contacts are also in close proximity to the peptide
(#5 A˚). Overall, these results indicate a strong cor-
relation between V . 1 residues and peptide–anti-
gen binding. Such a correlation provides a good
predictive tool to anticipate that any V . 1 sites in
the MHCI a1a2 domain or MHCII a1b1 domain
will likely be a peptide contact residue.
It is interesting to note that each HLA molecule
has a variability profile that is distinct from that of
the other HLA molecules (Figures 3 and 4). This is
best seen by examining the residues that are pep-
tide and/or TCR contact positions, as they display
the greatest variability. As an example, residue 62
is the most variable position in HLA-A but it has
low variability in HLA-B and is virtually constant
in HLA-C (Figure 3). These differences in localiz-
ation of the variability in HLA class I and HLA
class II molecules are shown dramatically when
variability is displayed on their 3D structures. In
Figure 5, the variability of HLA-A, HLA-B and
HLA-C molecules has been mapped onto their
molecular surface (Figure 5(A1), (B1) and (C1),
respectively) and corresponding worm represen-
tations (Figure 5(A2), (B2) and (C2), respectively).
Likewise, Figure 6 represents the variability of
HLA-DP, HLA-DQ and HLA-DR molecules dis-
played on their respective molecular surfaces
(Figure 6(A1), (B1) and (C1), respectively), with
corresponding worm representations (Figure
6(A2), (B2) and (C2)). In these Figures, variability
has been scaled into a two-color representation,
where blue indicates variable sites and red is for
invariant sites with blue, white and red shadings
representing positions with intermediate
variability.
A theme emerges from the analysis of these
Figures, which is common to class I and class II
molecules. First, variable positions (in blue) map
onto different sites in each of the HLA class I and
HLA class II molecules. As an example, in class I
the three residues with the highest variability are
residue 62, 9 and 114 in HLA-A (Figure 5(A2)),
residues 45, 67, and 116 in HLA-B (Figure 5(B2)),
and residues 9, 116, and 156 in HLA-C (Figure
5(C2)). Second, as most variable positions corre-
spond to residues contacting peptide (Figures 3
and 4; Table 4), variable residues map onto the b-
strands that form the base of the antigen-presenting
domain (for example residues 9 and 114 in HLA-A,
and residues b11, b13, b37 in HLA-DRB), as well as
in residues lining the walls of the peptide-binding
groove (for example, residue 67 in HLA-B, residue
156 in HLA-C, and residue b57 in HLA-DP and
HLA-DQ) (Figures 5 and 6). As anticipated, in
HLA-DP and HLA-DR HLA class II molecules, vir-
tually no variability maps onto their a1 domain 3D
structures. Interestingly, however, in HLA-DQ resi-
dues a44 and a50, two of the three most variable
positions were not identified as peptide contacts
(Figure 4). However, they are in the neighborhood
of the peptide, indicating they could contribute to
peptide binding in some other HLA-DQ allelic
Table 5. Number of variable HLA sites contacting pep-
tide and TCR
MHC V Peptide TCR a1a2 (b1) Total
HLA-A .0 24 (60.0) 17 (56.7) 95 168
0.5–1 9 (22.5) 8 (26.7) 20 34
.1 9 (22.5) 4 (13.3) 13 16
HLA-B .0 31 (77.5) 19 (63.3) 103 176
0.5–1 5 (12.5) 2 (6.7) 19 28
.1 14 (35.0) 2 (6.7) 15 17
HLA-C .0 18 (45.0) 6 (20.0) 40 103
0.5–1 7 (17.5) 3 (10.0) 14 31
.1 9 (22.5) 2 (6.7) 9 14
HLA-DP .0 30 (66.7) 10 (43.5) 32 40
0.5–1 4 (8.9) 0 (0.0) 13 20
.1 8 (17.8) 2 (8.7) 8 8
HLA-DQ .0 27 (60.0) 8 (34.8) 59 95
0.5–1 14 (31.1) 5 (21.7) 29 58
.1 9 (20.0) 2 (8.7) 15 15
HLA-DR V . 0 18 (40.0) 12 (52.2) 61 107
0.5–1 4 (8.9) 3 (13.0) 10 32
.1 10 (22.2) 3 (13.0) 14 16
In HLA class II, 45 and 23 positions were identified as poten-
tial peptide and TCR contacts, respectively. In class I, 40 and 30
sites were identified as potential peptide and TCR contacts,
respectively. Percentages shown in parentheses are relative to
the total number of residues contacting peptide or TCR.
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variants. Third, although more limited, some varia-
bility is seen in the molecular surface of the MHC
molecules in the regions contacted by the TCR. The
extent of this variability differs among the various
HLA molecules. Thus, among class I molecules, the
HLA-A alleles appear to manifest the greatest vari-
ation among surface exposed residues in TCR con-
tact areas (Figure 5(A1)). Moreover, residue 62 (a
TCR contact site) in the a1 helix is the most variable
residue in HLA-A. In contrast, in HLA-B and HLA-
C, none of the TCR contact sites was among the
most variable and, furthermore, the more variable
residue in this region (residue 163) is located in the
a2 helical region and is, in addition to a TCR contact
site, a peptide contact site. In class II, the variability
in the TCR contact regions also differs for each sub-
type. Thus, this region is less prone to variation in
HLA-DP (Figure 6(A1)), intermediate in HLA-DR,
and most variable in HLA-DQ. Among the TCR con-
tact sites, residues 70 and 71, which are also peptide
contacts, have the largest variability in both HLA-
DQ and HLA-DR. Note how the b1 variability in
HLA-DQ and HLA-DR vis-a-vis TCR contacts
involves the Va docking site and is a region without
variability in the corresponding a2 surface of HLA-
A, -B and -C molecules. Whether this difference
relates to the more restricted docking topology of
class II MHC binding T-cells31 remains to be
determined.
Sequence logos of HLA contacts sites with
peptide and TCR
Variability values within the HLA molecules
never exceed 2.5, indicating that there are only a
few prevalent amino acids permitted at any site,
presumably a consequence of structural and/or
functional constraints. Given that the majority of
polymorphic sites are peptide and/or TCR con-
tacts, a better understanding of the interaction of
HLA molecules with the peptide and TCR will fol-
low from knowing what specific amino acids types
are present. Because V offers identification of the
polymorphic sites without information on the
amino acids types present at a given position, we
compiled the amino acid residues at positions
identified as primary peptide contacts from pri-
mary HLA sequence alignments (positions indi-
cated with inverted black triangles in Figures 3
and 4) and generated a consensus sequence logo
(Figure 7). Likewise, a second set of sequence
logos was generated for each of the HLA molecules
Figure 5. The 3D-structure mapping of the sequence variability in a1a2 domains of HLA class I molecules. Sequence
variability in the a1a2 domains of HLA-A, HLA-B, HLA-C molecules was mapped onto their molecular surfaces (A1,
B1 and C1), as well as onto their worm representations (A2, B2 and C2, respectively). Consensus amino acids in pos-
itions with the greatest variability are indicated in the worm representations. The consensus amino acids in the poly-
morphic positions that are TCR contacts are indicated in the molecular surface diagrams. Variability is represented in
a relative two-color scale of blue and red, where red indicates non-variable regions and blue indicates variable regions.
White in this two-color variability scale indicates regions of intermediate variability. The Figures were rendered from
the following PDB files: HLA-A, 1DUY; HLA-B, 1A1N; HLA-C, 1IM9.
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(Figure 8) from the residues identified as TCR con-
tacts sites (color shaded residues in Figures 3 and
4). In such a sequence logo, each amino acid type
at a given position is represented by its corre-
sponding symbols with a height proportional to
both the sequence information in that position and
its frequency (see Materials and Methods). In this
representation, the greater the number of amino
acids present at a given site, the lower the sequence
information at that site. Correspondingly, the
height of the stack of symbols in that position is
small, with each amino acid represented by a size
that is proportional to its frequency. In any pos-
ition, the most frequent amino acid is on the top
of the stack. On the other hand, if only one residue
is present at a given position, then the height is
equal to the maximum sequence information at
that site, which for a system of 20 symbols is 4.3
(Materials and Methods, equation (2)).
Inspection of HLA peptide-binding sequence
logos identifies two types of residues: those that
are constant (invariant) and those that are variable
(polymorphic or dimorphic). Constant residues
are identical between all HLA class I molecules,
providing a common conserved framework for the
binding of a peptide in a gene and allele-indepen-
dent manner. In HLA class I molecules, these are
exemplified by residues Y59, Y84, Y123 and Y159
(Figure 7(A)–(C)). Those residues engage in a con-
served network of H bonds with the N and C ter-
minii of the peptide.6 Similarly, in class II, residues
conserved in HLA-DP, HLA-DQ and HLA-DR
include aR76, bW61 and bN82 (Figure 7(D)–(F)),
form hydrogen bonds with the backbone of the
peptide and thereby provide a binding affinity
that is also gene and allotype-independent. Note
that no conservation is anticipated between HLA
class I and HLA class II molecules, since binding
of peptides to these molecules occurs in a very
different mode. Additional invariant residues to
those conserved between all HLA molecules of the
same class, can be found among the alleles belong-
ing to the same gene. These sets of additional gene-
specific invariant residues can be quite distinct
among different HLA molecules (Figure 7), provid-
ing binding features shared by all alleles derived
from the same gene. Finally, peptide-binding
specificity is modulated at the allelic level by the
polymorphic residues. The combination of
variable and constant residues is also gene-specific.
For example, residue 45 is an invariant Met in
HLA-A (Figure 7(A)), conserved Gly in HLA-C
Figure 6. The 3D-structure mapping of the sequence variability in a1b1 domains of HLA class II molecules.
Sequence variability in the a1b1 domain of the HLA-DP, HLA-DQ, HLA-DR molecules appears mapped onto their
molecular surfaces (A1, B1 and C1), as well as onto their worm representations (A2, B2 and C2, respectively). Consen-
sus amino acids in positions with the greatest variability are indicated in the worm representation. The consensus
amino acids in the polymorphic positions that are TCR contacts are indicated in the molecular surface diagrams. Varia-
bility is represented as in Figure 5. HLA-DQ and HLA-DQ Figures were rendered from PDB files 1JK8 and 1HXY,
respectively. HLA-DP was rendered from a model obtained as indicated in Materials and Methods. For simplicity,
only the core of the peptide (nine residues) fitting into the binding groove of the HLA class II molecules is shown.
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(Figure 7(C)) but in HLA-B is either Glu, Thr, Lys
or Met. Likewise, residue a52 is a conserved Phe
in HLA-DP (Figure 7(D)), a conserved Ala in
HLA-DR (Figure 7(F)), and either an Arg or a Gly
in HLA-DQ (Figure 7(E)). This gene-specific combi-
nation of polymorphic and constant residues
suggest that, in general, peptides binding to HLA
molecules encoded by the same gene are likely to
be more similar to each other than to other pep-
tides binding to HLA allelic variants derived from
different genes.
Comparison of sequence logos on HLA-TCR
contact sites is also informative. As shown in
Figure 8, many of these TCR contacts on HLA are
conserved. In the case of MHC class I, 18/30
HLA-A, 26/30 HLA-B and 25/30 HLA-C contacts
are essentially invariant. Likewise, for HLA class
II, 21/23 DP, 16/23 DQ and 17/23 DR residues are
conserved. These conservations define HLA gene-
specific TCR docking sites. In addition, note that
some of the HLA-TCR contact sites are poly-
morphic. The extent of this variability component
differs for the individual HLA genes. With respect
to TCR contacts, polymorphisms within HLA-A,
Figure 7. Consensus sequence logos of HLA class I and HLA class II peptide contact sites. HLA peptide binding
consensus sequence logos are given for MHC class I HLA-A (A), HLA-B (B), and HLA-C (C), and for MHC class II
HLA-DP (D), HLA-DQ (E), and HLA-DR (F). Only primary peptide contacts were considered for these sequence
logos (residues indicated with black triangles in Figures 3 and 4). HLA sites from which the sequence logos were
derived are indicated under the amino acid symbols. Also indicated under the amino acid symbols is the domain
location of the residues (a1 or a2 domain of class I MHC molecule, and likewise the a1 or b1 domain of class II
MHC molecules). These sequence logos show all the amino acid types present at a given position with a size that is
proportional to its frequency and total sequence information in that position (see Materials and Methods for more
details). Thus, the more amino acid residues present in a given site, the lower will be the sequence information at
that site (bits) and, correspondingly, the smaller will be the height of the stack of symbols. Yet each amino acid residue
in the stack will be proportional to its frequency in that position. On the other hand, if only one amino acid residue is
present, the symbol representing that residue will reach heights of 4.3 bytes, the maximum information content for a
system of 20 symbols.
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DQ and DR have the greatest contribution to allelic
variability. In Figure 8, we have also distinguished
between residues that contact the Va (indicated
with a red rectangle under the sequence), Vb (blue
rectangle) or both domains (green rectangle). Note
how the TCR makes more potential contacts with
the residues in the MHCI a2 helix than with resi-
dues in the a1 helix. This is significant, taking into
account the fact that TCR contacts are representa-
tive of a summation of all TCR–pMHC structures
analyzed and especially given that docking
variability is greatest along the MHCI a1 helix,
thereby exaggerating the number of such potential
contacts in favor of TCR Vb interaction. That more
Va residue contacts with MHCI are observed
further underscores the key role of Va in pMHC
ligand recognition.
From the HLA TCR contact logos, it is clear that
many residues are conserved among the molecules
encoded by the three HLA class I genes. For
example, contact residues such as E58, Y59, D61,
K68, Q72, K146, E154, Q155, R157, Y159, G162 and
R170 are constant and conserved in all three sub-
groups of HLA molecules (Figure 8(A)–(C)). Simi-
larly, a majority of the HLA class II TCR contact
residues are constant among HLA-DP, HLA-DQ
and HLA-DR (Figure 8(D)–(F)) despite the fact
that HLA class II molecules are more divergent
than HLA I molecules (Figure 2). These constant
contact residues in all HLA class II molecules
include aK39, aQ57, aL60, aN62, aA64; bQ61,
bE69, bR72, bD76 and bH81. Nevertheless, there
are differences between the HLA-DP, HLA-DQ
and HLA-DR sequence logos affecting invariant
residues (for example, residue a68 is Asn in HLA-
DP, His in HLA-DQ and Ala in HLA-DR). Note
also that the amino acid types at the polymorphic
sites can be quite distinct (for example, at residue
b70 and b71).
In the case of the HLA class II TCR contacts, the
TCR Vb domain interacts with MHC residues that
are more hydrophobic (five of eight) than those
contacted by the TCR Va domain (one of nine). In
contrast, eight of nine TCR Va contacts are with
hydrophilic residues on MHCII. This observation
might indicate that the interaction between the
TCR b chain and the MHCII a1 helix provides a
major contribution to total binding energy within
the TCR–pMHC complex, whereas the interaction
of the TCR Va domain and the MHCII b1 helix
may provide greater specificity through this
docking.
Implications for TCR–pMHC recognition
TCRs recognize peptide antigens only when pre-
sented in the context of a given MHC molecule, a
phenomenon referred to as MHC restriction.32 – 34
Such MHC-dependent recognition of the peptide
by the TCR is so precise that, in general, a TCR
will recognize pathogenic antigens presented by
self-MHC molecules but ignore the same peptides
Figure 8. Consensus sequence
logos for HLA class I and HLA
class II TCR contact sites. HLA
TCR consensus sequence logos are
presented for MHC class I HLA-A
(A), HLA-B (B), and HLA-C (C),
and for MHC class II HLA-DP (D),
HLA-DQ (E), and HLA-DR(F).
HLA sites from which the sequence
logos were derived are indicated
under the amino acid symbols. The
domain location of the residues (a1
or a2 domain in class I MHC mol-
ecule, and likewise the a1 or b1
domain of class II MHC molecules)
is indicated under the amino acid
symbols. TCR contact sites were
located in the helical region of the
a1 and a2 domain of MHC class I,
and likewise in the helical region of
the a1 and b1 domains, with the
exception of residue 39, which is
located in the S3–S4 loop of the a1
domain of HLA class II. MHC con-
tacts to Va, Vb and both Va plus
Vb domains are indicated by red,
blue and green rectangles,
respectively.
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when presented by foreign MHC molecules. The
importance of the MHC context for TCR-based rec-
ognition of peptide antigens is evident in the 3D
structures of TCR–pMHCI(II) complexes: these
structures reveal a topologically conserved TCR–
pMHC docking mode that generally maximizes
the contact area between the TCR and the MHC
molecule.30,35 – 37 Up to two-thirds of atomic contacts
between the TCR and the pMHC complex are with
the MHC itself.36
The TCR is composed of an a and b chain, each
encoded by variable, randomly rearranged V and
(D)J segments.38 Variability is concentrated in the
complementarity-determining regions (CDRs):
CDR1 (a,b) and CDR2 (a,b) are encoded by the
germline V segments, whereas the CDR3 (a,b)
loops originate from the junction of the V(D)J
elements and display greater variability due to
junctional diversification mechanisms. The dock-
ing of the TCR with the pMHC ligand is such that
the Va domain of the TCR is closest to the N-term-
inal residues of the antigenic peptide, whereas the
Vb domain of the TCR is closest to the C-terminal
segment.39 Moreover, the CDR1 (a,b) and CDR2
(a,b) loops interact with conserved residues over
the long a1 and a2 (b1) helices of the MHC mol-
ecule, while the more variable CDR3 (a,b) loops
are positioned to primarily contact the peptide.
The central location of the CDR3s in the pMHC
complex provides an explanation of their role in
determining specificity. Despite the conserved
diagonal docking mode of the TCR onto the
pMHCI, there is variation among the different
TCR–pMHCI complexes.30,36 In addition, the dock-
ing of the D10 TCR onto the mouse class II MHC
molecule IAk has been described as close-to-
orthogonal, likely reflective of more limited TCR–
pMHCII orientations resulting from the p-1 to p-3
extension of peptides bound to MHCII
molecules.31,36 The TCR–pMHC interaction further
deviates with respect to twist, tilt and shift.30,40
The reactivity of the pre-selected TCR repertoire
towards the pMHC argues strongly that MHC-
reactivity is inherent in the TCR germline elements,
hence independent of positive and negative
selection.41,42 Moreover, such intrinsic reactivity
would suggest a co-evolution of the TCR genetic
components towards the recognition of the MHC
molecule, implying a bias of the TCR germline to
optimize recognition of MHC molecules through
specified TCR contact residues. The TCR contact
sequence logos of HLA class I versus HLA class II
molecules (Figure 8) are reflective of this co-evol-
ution and, furthermore, support the existence of
TCR restriction that is class dependent (MHCI ver-
sus MHCII TCR restriction). Va-dependent T-cell
repertoire selection through preferential recog-
nition of MHC class I or class II molecules has
been shown in several experimental systems.43,44
In this regard, Sim et al.43 found that in the mouse
individual residues in either the CDR1 or CDR2 in
the TCR Va chain were sufficient to shift selection
from the CD4þ to the CD8þ subset. Since compari-
son of TCR contact sequences logos of class I and
class II HLA molecules (Figure 8) identifies distinct
class I versus class II conserved residues as being
contacted by the TCR Vb domain, some bias in
TCR Vb-encoded germline usage can be antici-
pated. Note that TCR V-germline encoded selection
of the repertoire through preferential recognition of
MHC class I or class II molecules is not absolute, as
the same Va elements can be utilized by both CD4þ
and CD8þ compartments. Given that the inter-
action of the TCR with the pMHC is extremely flex-
ible, and that most of the TCR contact residues in
the MHC contribute equally to the total energy of
the binding,45 favorable contacts between the vari-
able CDR3 loops and the pMHC could compensate
for strict differential Va segment usage in the CD8þ
and CD4þ subsets. Candeais et al.46 reported that
the repertoire of transgenic mice expression only
the Vb17þ segment showed dissimilar CDR3s in
CD4þ versus CD8þ cells. As the CDR3 of the TCR
primarily senses the peptide in the MHC groove,
these observations highlight the impact of the pep-
tide in the restriction of the TCR.
Inspection of HLA TCR contact sequence logos
(Figure 8) makes it apparent that class I-HLA-
restricted TCRs will have little potential to interact
with HLA class II molecules and vice versa, given
the differences in contact residues of the two HLA
classes. With respect to TCR crossreactivity with
alleles from different genes, this appears unlikely
because of the existing differences in the TCR con-
tacts sites, and because HLA-A versus HLA-B mol-
ecules, for example, bind to very different sets of
peptides for presentation.47 On the other hand,
TCR crossreactivity between distinct HLA allelic
variants derived from the same MHCI (or MHCII)
gene is more probable, being likely a major source
of alloreactivity. In this case, a similar constellation
of bound peptides contributes further to TCR reac-
tivity. For example, a crossreactive H1.7 TCR
specific for an influenza virus peptide (HA)
restricted by HLA-DR1(DRA p 0101xDRB p 0101)
can bind to the same peptide presented by HLA-
DR4(DRA p 0101xDRB p 0401.48
Implications for alloreactivity
Approximately 1–10% of T-cells are alloreactive,
reacting strongly with foreign HLA allotypes to
which they were never exposed.49 This contrasts
with a multiple order of magnitude lower fre-
quency of foreign peptide/self-MHC specific T-
cells. Alloreactive T-cells are the major cause of
allograft rejection.1 T-cell allorecognition has been
divided into two types, referred to as direct and
indirect, that differ in their molecular mechanism.
The indirect pathway occurs when T-cells recog-
nize peptide antigens derived from foreign
(donor) MHC molecules presented by self-MHC
(recipient).50,51 This mechanism is applicable to
any polymorphic gene products (i.e. so-called
minor histocompatibility antigens) of the donor
presented by the self-MHC.52 On the other hand,
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the direct pathway involves T-cell recognition of
intact allogeneic pMHC molecules.53 It is believed
that the indirect pathway may play an important
role in chronic allograft rejection,54 whereas the
direct pathway is the main contributor to acute
graft rejection.51 The high expression level of HLA
molecules per cell and their allelic variability are
the obvious molecular bases of the indirect path-
way of alloreactivity.
While the precise molecular basis of direct allor-
eactivity is not fully resolved, recent structural
studies of alloreactive TCRs in complex with allo-
geneic pMHCI molecules55 – 57 indicate that these
molecules engage in a binding mode that is like
that of TCRs in complex with self-MHCI mol-
ecules. In these complexes, there is a shift in the
extent of TCR Va and TCR Vb domain interactions
with the pMHC ligand towards the TCR Vb
chain; Vb makes more contacts than Va in the
2C/H-2Kbm3-dEV855 and BM3.3/H-2Kb-pBM1
complexes,57 while Vb contributes equally in the
Kb5-C20-pKB1/Kb complex.56 Overall, these
studies do not define a unique structural feature
of alloreactive TCRs, but instead show that allore-
cognition is similar to foreign antigen/self-MHC
recognition, implying that subtle differences in the
MHC and/or conformation of the peptide can trig-
ger an alloresponse.
Two main models have been proposed to explain
direct alloreactivity. On the one hand, it has been
proposed that alloreactive T-cells recognize allelic
polymorphisms at TCR contact sites of the MHC
molecule.58 Indeed, polymorphisms in the TCR
contact sites of the MHC have been reported to
lead to alloreacitivity for both class I59 and class II
allogeneic MHC.60 However, alloresponse is often
directed against allogeneic MHC molecules dis-
playing amino acid sequencing differences only in
the buried portion of the MHC binding groove,
which is inaccessible to the TCR.57,61 To account
for these observations, a second model for alloreac-
tivity has been proposed, driven by the specific
peptide presented by the allogeneic MHC
molecules.62 In this second model, the high fre-
quency of alloreactive T-cells derives from the fact
that allogeneic MHC molecules present “new”
peptides to which T-cells from the recipient were
never exposed. Although these two models are
not necessarily exclusive, current 3D structural
studies on alloreactive TCR complexed with allo-
geneic MHC molecules have highlighted the role
played by peptides in alloreactivity. For example,
comparison of the 2C TCR in complex with an allo-
geneic MHC (H-2Kbm3-dEV8) and the 2C TCR in
complex with self-MHC (H-2Kb-dEV8) has offered
insights about how allogeneic MHC molecules can
be sensed by the TCR via the bound peptide.57
There are two amino acid differences between the
H-2Kbm3 and H-2Kb molecules. The Asp77Ser
mutation that imbues the H-2Kbm3-dEV8 with allor-
eactive properties is located beneath the peptide,
making no contact with the TCR. However, this
allogeneic mutation is enough to cause a confor-
mational change in the peptide, so that the same
peptide is presented differently by the allogeneic
and syngeneic MHC. This subtle difference is the
basis of the alloreactive response by the 2C TCR.
The present study of HLA polymorphism, with-
out dismissing the role of TCR contacts as potential
effectors for alloreactivity, endorses the notion that
peptide-driven recognition of allogeneic HLA mol-
ecules will likely be the most frequent cause of
alloreactivity. Indeed, sequence variability analyses
of HLA molecules indicate that most polymorphic
sites occur in peptide-binding positions (Table 5;
Figures 3, 4 and 7) not readily accessible to the
TCR (Figures 5 and 6). These polymorphic peptide-
binding sites will result in allelic HLA variants
having different peptide specificity, likely present-
ing a new pool of peptides that TCRs will
recognize as foreign, since these peptides were not
encountered during thymic maturation. In con-
trast, TCR contacts in the HLA molecules in both
class I and class II are the subject of much more
limited polymorphic variability (Figures 3, 4 and
8; Table 5), indicating that at least during graft-
rejection, alloreactivity caused by this variability is
likely to be less frequent.
Materials and Methods
MHC sequences and multiple sequence alignments
Amino acid sequences of the human MHCI and
MHCII alleles were collected from the IMGT/HLA
database.13 Amino acid sequences were collected from
functional genes with sequences from pseudogenes
being discarded. Thus, amino acid sequences of the a
and b chains of the HLA-DP molecule (HLA-DPA, and
HLA-DPB, respectively) were obtained from the HLA-
DPA1 and HLA-DPB1 genes. Likewise, the HLA-DQA1
and HLA-DQB1 genes were the only sources of the
amino acid sequences for the a and b chains of the
HLA-DQ molecule (HLA-DQA, and HLA-DQB, respect-
ively). The amino acid sequences for the a chain of
HLA-DR (HLA-DRA) came from the HLA-DRA gene,
whereas the amino acid sequences for the b chain
(HLA-DRB) came from four distinct genes: HLA-DRB1,
-DRB3, -DRB4, and -DRB5. The amino acid sequences of
the class I HLA molecules HLA-A, HLA-B, and HLA-C
were encoded by the HLA-A, HLA-B, and HLA-C genes,
respectively. The number of sequences included in this
analysis are shown in Table 1. Only allelic sequences dif-
fering in at least one amino acid residue were con-
sidered. Multiple sequence alignment of allelic variants
of the HLA-A, HLA-B, and HLA-C class I molecules, as
well as of HLA class II molecules HLA-DPA, HLA-DPB,
HLA-DQA, HLA-DQB, HLA-DRA, and HLA-DRB were
carried out from the selected sequences (Table 1) using
CLUSTALW.63 Sequence numbering is based on that for
the 3D structures of the MHC molecules.
Sequence variability analysis and
consensus sequences
To quantify the diversity of human HLA molecules,
we have used a variability metric (V) formally identical
with the Shannon entropy equation.20 For a multiple
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sequence alignment, V per site will be given by:
V ¼ 2
XM
i¼1
Pi log2Pi ð1Þ
where Pi is the fraction of residues of amino acid type i,
and M is equal to 20, the number of amino acid types.
Given that sequence alignments were mostly ungapped
but contained many sequence fragments, gap symbols
were considered as no data. V ranges from 0 (only one
amino acid type is present at that position) to 4.322 (all
20 amino acids are represented equally in that position).
It is important to note that at least 20 sequences are
required in order to achieve the maximum value V ¼ 4.3.
Consensus sequences of HLA positions contacting the
peptide and TCR were obtained and displayed using
sequence logos.64 In this approach, each of the residues pre-
sent in a position is represented with a height that is pro-
portional to its frequency, and the height of the entire
stack is proportional to the total information content (R) in
that position. R per site is given by the following equation:
R ¼ 4:32 V ðbits per positionÞ ð2Þ
where 4.3 is the maximum variability for 20 symbols, and
V is the variability in that position, given by equation (1).
Sequence information is given in bits.
Sequence contact maps
MHC residues contacting peptide, TCR, CD4 and CD8
were obtained by analyzing the relevant 3D structures
shown in Table 2. Briefly, MHC residues were considered
to contact the peptide or the TCR if they were at a dis-
tance of 5.0 A˚ or less. The chosen contact distance was
larger than the standard van der Waals distance (4.0 A˚)
because MHCs, peptides and TCRs are all highly vari-
able molecules and, hence, all possible contacts cannot
be represented by the limited number of available 3D
structures. Contacts between MHC and peptides and
MHC and TCRs were compiled after summing all con-
tacts resulting from the analyses of individual 3D struc-
tures. Nevertheless, MHC–peptide contacts were
obtained separately for the HLA-A, HLA-B, HLA-C,
HLA-DP, HLA-DQ, HLA-DR molecules from the repre-
sentative X-ray crystal structures (Table 2). In the case of
HLA-DP, for which there is no available 3D structure,
peptide contacts were obtained from the analysis of a
model (DPA1p0103xDPB1p0201) in complex with the
nonamer peptide ligand YAASSYLSL derived from
human Ig lambda chain. Potential HLA class I contacts
with the TCR were derived from the analysis of all avail-
able X-ray crystal structures of class I MHC–TCR com-
plexes, including those from mouse MHCI molecules
(Table 2). Likewise, HLA class II contacts with the TCR
were obtained from all available class II MHC–TCR
complexes. HLA class II residues contacting CD4 and
HLA class I residues contacting CD8 were obtained
from the relevant X-ray 3D structures (Table 2) using a
distance of 4.5 A˚. All contacts were subject to visual
inspection using the program RASMOL.65
Molecular graphics and modeling
A molecular model of the HLA-DP a1b1 domain
(DPA1p0103xDPB1p0201) with the bound nonamer pep-
tide YAASSYLSL from human Ig l chain was derived
by homology modeling from the 3D coordinates of
HLA-DR1(DRB1p0101) (PDB: 1HXY) using the package
MODELLER.66 Sequence variability of MHC molecules
was mapped onto the molecular surface or worm rep-
resentations of the MHC molecules using the program
GRASP67 via a B-factor. A program for projecting the
variability for a multiple sequence alignment to a 3D
structure is available on-line at the H2PDB web server
hosted by the Molecular Immunology Foundation†.
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